EQS-News: Eckert & Ziegler becomes European contract manufacturer for Telix's innovative Phase III ProstACT GLOBAL study
EQS-News: Eckert Ziegler SE
/ Key word(s): Contract/Alliance
Berlin, August 13, 2024 - Eckert Ziegler and Telix Pharmaceuticals Limited (Telix) today announced the signing of a significant multi-year agreement under which Eckert Ziegler will serve as the European contract manufacturing organization (CMO) for Telix's ProstACT GLOBAL Phase III study. The contract covers the supply of the entire European patient base from the state-of-the-art facility in Berlin. In addition, Eckert Ziegler will also be a provider of the crucial starting material in the form of their high-purity, non-carrier added GMP-grade Lutetium-177 (Lu-177). Telix's ProstACT GLOBAL study is investigating the benefits and risks of Lutetium (Lu 177) rosopatamab tetraxetan, a radio-labeled antibody drug conjugate (rADC), in adult males with prostate-specific membrane antigen (PSMA) positive prostate cancer in combination with standard of care. "We are happy to further expand our long-standing and successful collaboration with Telix," said Dr. Harald Hasselmann, CEO of Eckert Ziegler SE. "This contract underlines not only the importance of our leading-edge facility in Berlin, but also our role as an integral service provider in the continuously growing radiopharmaceutical market." Darren Patti, Group Chief Operating Officer of Telix, added: "The decision to work with Eckert Ziegler is based on their outstanding expertise and the quality of their facilities. We are convinced that this continued strategic partnership will contribute significantly to the success of our ProstACT GLOBAL study." The collaboration marks an important step in both companies' ongoing efforts to advance innovative solutions in the field of radiopharmaceuticals. Eckert Ziegler operates several CMO sites worldwide and offers a range of other services along the entire value chain. About Eckert Ziegler Contact
13.08.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | Eckert Ziegler SE |
Robert-Rössle-Str.10 | |
13125 Berlin | |
Germany | |
Phone: | +49 30 941084-138 |
Fax: | +49 30 941084-0 |
Internet: | www.ezag.de |
ISIN: | DE0005659700 |
WKN: | 565970 |
Indices: | SDAX, TecDax, |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1966007 |
End of News | EQS News Service |
|
1966007 13.08.2024 CET/CEST
Eckert & Ziegler Strahlen- und Medizintechnik AG Aktie
Die Eckert & Ziegler Strahlen- und Medizintechnik AG Aktie verzeichnet starke Buy-Einschätzungen ohne jegliche Sell-Einschätzungen.
Die Community prognostiziert für Eckert & Ziegler Strahlen- und Medizintechnik AG ein Kursziel von 95 €, was den aktuellen Kurs von 40.74 € weit übertrifft.